India's Bacteria Fight Back: Superbugs Resist Treatment

India is grappling with a significant rise in antibiotic resistance, with approximately 35% of bacterial infections in clinical settings now defying first-line treatments. This escalating crisis is underscored by a concerning drop in carbapenem susceptibility, a last-resort medication, to below 30% for certain severe bacterial strains.

The distinction between antibiotic resistance and tolerance is vital. Resistance involves permanent genetic mutations or acquired genes, enabling bacteria to actively neutralize drugs or expel them. These 'superbugs' continue to multiply, rendering standard treatments ineffective and posing a risk of person-to-person spread.

Antibiotic tolerance, however, is a more passive survival tactic where bacteria enter a dormant state, evading drugs designed to target active cellular machinery. These 'persister cells' can reactivate once medication stops, leading to recurring infections, a common issue in India. Tolerance can also provide the necessary time for bacteria to develop full resistance.

Addressing this multifaceted threat requires a shift towards 'smarter medicine.' Key strategies include mandating the completion of full antibiotic courses to eliminate dormant bacteria, improving diagnostic accuracy through culture and sensitivity tests, and strictly avoiding antibiotics for viral infections to prevent unnecessary resistance development.